 SMC Global Securities Ltd Q2 FY2025-26 consolidated net profit declines to Rs. 20.65 crores
SMC Global Securities Ltd Q2 FY2025-26 consolidated net profit declines to Rs. 20.65 crores Rajoo Engineers Ltd Q2FY26 consolidated profit at Rs. 14.18 crores
Rajoo Engineers Ltd Q2FY26 consolidated profit at Rs. 14.18 crores Inventurus Knowledge Solutions Ltd consolidated Q2 FY2025-26 PAT climbs to Rs. 180.71 crores
Inventurus Knowledge Solutions Ltd consolidated Q2 FY2025-26 PAT climbs to Rs. 180.71 crores IFB Industries Ltd consolidated PAT for Q2FY26 jumps to Rs. 50.79 crores
IFB Industries Ltd consolidated PAT for Q2FY26 jumps to Rs. 50.79 crores Share India Securities Ltd consolidated Q2 FY26 net profit at Rs. 92.91 crores
Share India Securities Ltd consolidated Q2 FY26 net profit at Rs. 92.91 crores 
              Mumbai, October 19, 2006: Lupin Ltd today announced that Mr.Edward R.Roberts has joined the company's board as an Independent Director.
Mr.Roberts, a British Citizen, residing in Germany, is a 1959 pharmacy graduate from Leicester University. He has wide experience in the international pharma industry. He is the Chairman of the Board of "Biopartners", (a Swiss biotech company) and "Merz Pharma", (a well known German pharma company). He is also a member of the Board of "Icon", a listed US Contact Research Organisation. He is also an advisor to "Avista", a US private equity company.
Till the year 1998, he was the Head of Pharmaceuticals at 'E Merck', a leading German pharma company, prior to which he spent 27 years at 'Eli Lilly' was as President of 'Elanco', the agricultural division of 'Eli Lilly'.
Welcoming Mr.Robers on the Board, Dr.Desh Bandhu Gupta, Chairman, said "I am delighted that an internationally renowned person like Mr.Roberts has accepted our invitation to join the Board. His enormous experience and deep knowledge of the International pharma business will prove to be a valuable asset for Lupin."